Unable or unwilling to discontinue use of any drug known to be a strong or moderate inhibitor or inducer of CYPA (prohibited inducers and inhibitors must be discontinued within  weeks prior to first dose of study drug); unable or unwilling to discontinue use of any proton pump inhibitor
Patients must not be pregnant or breast feeding, or unable or unwilling to use proper contraception during the study and up to  months following study completion (for treatment phase)
Patients not able or unwilling to travel for proton therapy
Unable/unwilling to undergo bone marrow sampling
Subjects must be unwilling or unable to tolerate other non-study systemic chemotherapy.
For female patients of childbearing potential (defined as having had a menstrual period within the past  months): a positive serum pregnancy test (?-human chorionic gonadotropin [? HCG]) within  days prior to enrollment; or unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment; or if breastfeeding, unwilling or unable to stop breastfeeding while on study treatment.
Patients unable or unwilling to adhere to the study assessment schedule.
Patients with human immunodeficiency virus (HIV) who are unable or unwilling to stop antiretroviral therapy for the duration of therapy may not be enrolled
Patients who are unwilling or unable to undergo an apheresis for production of their vaccine
Patients unable or unwilling to return to the transplant center for their assigned treatments.
Patients unable or unwilling to undergo a biopsy for research during the screening period, - weeks into the course of therapy and at the time of progression
Subjects unable to adhere to the dietary modification outlined in the protocol.
Subjects must not be pregnant or unwilling to undergo pregnancy screening
Unable or unwilling to follow post-therapy radiation protection procedures
Unwilling or unable to discontinue disallowed disease-modifying antirheumatic drugs (DMARDs) for treatment of SSc prior to mobilization
Patient is unwilling or unable to follow the study schedule for any reason
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Patients who, in the investigator's judgment, are unwilling or unable to consent to and return for recommended post-treatment scans as outlined in this study
All patients with - metastatic brain lesions who are considered eligible for single-fraction, frame-based SRS, who are unable or unwilling to undergo frame-based SRS
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for  weeks after discontinuation of therapy
Unable or unwilling to tolerate an intracranial MRI
Subject is unable or unwilling to discontinue use of prohibited medications
Patient is unwilling or unable to follow the study schedule for any reason
Unwilling or unable to stop oral supplemental vitamin D
Unable to attend sessions
Unable or unwilling to swallow ARQ  or anastrozole or comply with chemotherapy regimen
Patients who are unable to perform the breath hold scan
For female patients of childbearing potential (i.e., have had a menstrual period within the past  months): unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment.
Unable to receive prophylactic treatment for pneumocystis
Unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least  days (fruits and juices for at least  days) prior to day  of FOLFIRI + bevacizumab initiation
Unwilling or unable to complete study diary
Unable or unwilling to undergo a  day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;
Breast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to  months after end of ibrutinib.)
Unable or unwilling to adhere to the study-specified procedures and restrictions
Participants unwilling or unable to discontinue use of prohibited therapies, including any cytotoxic chemotherapy, radiotherapy, immunotherapy or biologic agent (approved or investigational) for the treatment of TCC are ineligible
Is unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain
Patients of childbearing age who are unwilling to practice contraception or other means of avoiding pregnancy
Unable or unwilling to undergo protocol required thromboembolism prophylaxis(for Cohort C, this will be only for the subjects who have a history of VTE)
Is unwilling to adhere to contraception criteria from time of enrollment in study to at least  days after last dose of IP.
Is unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain
Patient is unwilling or unable to follow the study schedule for any reason
Unable to receive prophylactic treatment for pneumocystis
Unable or unwilling to undergo antithrombotic prophylaxis
Unable or unwilling to discontinue use of prohibited medications for at least  days prior to the first dose of study drug and for the duration of the study
Sexually active individuals capable of becoming pregnant who are unable or unwilling to use effective form(s) of contraception during time enrolled on study and for  year post-transplant
Patients unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least  days prior to day  of FOLFIRI initiation
Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for  weeks of a drug (whichever is longer) prior to Visit  and for the duration of the study
EXPANSION COHORT ONLY: Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for  weeks of a drug (whichever is longer) prior to visit  and for the duration of the study
Unable or unwilling to adhere to the study-specified procedures and restrictions
Is unwilling or unable to abide by the requirements of the study.
Unwilling or unable to take oral medication
Unable to obtain diagnostic imaging
In Part , unable or unwilling to consent to provision of tumor tissue for GR assay
Patients currently taking statins who are unwilling or unable to refrain from using statins  hours before, the day of, and  hours after each MLN administration
PART II: Oncology participants must be unwilling or ineligible for further radiation or chemotherapy at the time of enrollment into study
Patients who are unwilling or unable to refrain from using hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) starting  days before the initial study drug administration and throughout the study will not be permitted to enroll
Unable to complete quality of life questionnaires
Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
Patients who are unable or unwilling to undergo antithrombotic therapy.
For female subjects of childbearing potential (i.e., have had a menstrual period within the past  months): a positive serum pregnancy test (?-human chorionic gonadotropin) within  days prior to enrollment; or unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment
Unable or unwilling to discontinue use of prohibited medications for at least  days prior to the first dose of topotecan/pazopanib and for the duration of the study
Unwilling or unable to participate in group RP sessions delivered via the Partners Telehealth videoconferencing software
PATIENTS: Unable to complete baseline interview.
Unable to complete the baseline interview
Unable or unwilling to discontinue consuming soy-based food or supplements while participating in this study
Unwilling to undergo phlebotomy
Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)
Unwilling to undergo routine follow-up
Are unable or unwilling to discontinue anxiolytics within  hours of education sessions
Subjects who are unable or unwilling to discontinue use of prohibited medications
Subjects who are unable to complete the symptom diary
Are unwilling to receive intensive (e.g. +) chemotherapy, or
Unable to complete the baseline assessment forms or to understand the recommendations for participation in the study
Be unable to complete the baseline assessment forms or to understand the recommendations for participation in the study
Patient or family is unable or unwilling to self/home administer subcutaneous experimental drug; study nurse or physician will train individuals on proper administration techniques
Be unable or unwilling to discontinue anxiolytic medication within  hours of intervention sessions
Is unwilling or unable to agree to swish and spit the study oral rinse three times per day during the study period
Those who are unable to understand Korean
Unwilling to complete online questionnaires
Currently pregnant or within  months post-partum, or unwilling to undergo pregnancy testing or report possible pregnancy promptly
Unwilling to complete baseline and follow-up questionnaires
Unable or unwilling to adhere to study-specified procedures
Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention
Unable to stand without assistance
Participants unwilling to complete the protocol ( month duration)
Unable to hold a breath
Patients on testosterone replacement therapy who are unwilling to discontinue
Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial
Patients unwilling to undergo serial non-invasive imaging
Patients unwilling to undergo craniotomy
Unwilling or unable to receive home health care
Unable to respond to text messages and questions or unable download the study app
Unable to see the app and study materials and videos (i.e., are blind, deaf)
Fox Chase Cancer Partners sites who do not agree to chart audit procedures or providers are unable or unwilling to participate in the educational initiative
Individuals who are unable to complete study materials
Unable to fast due to medical reason such as pregnancy
Men whose partner is unwilling or unable to avoid pregnancy
Lactose-intolerance or are unwilling/unable to consume the protocol-specified standardized high-fat, high-calorie breakfast.
